What's covered under the Article

Shukra Pharmaceuticals Limited has announced that it has received approval from BSE Limited (Bombay Stock Exchange) for the Sub-Division of Equity Shares of the company. Following this approval, a new ISIN number (INE551C01044) has been assigned to the company’s equity shares.

Approval Details and Sub-Division

As per the BSE notification dated March 19, 2025 (Notice No.: 20250319-43), the new ISIN (International Securities Identification Number) has been allocated due to the sub-division of equity shares from a face value of Rs. 10/- to Re. 1/- per share. This sub-division was approved by BSE Limited in its letter dated March 20, 2025.

Key Information Regarding the Sub-Division

• Company Name: Shukra Pharmaceuticals Limited
• Scrip Code: 524632
• Old Face Value: Rs. 10/- per share
• New Face Value: Re. 1/- per share
• New ISIN Number: INE551C01044
• Effective Date: March 21, 2025

Trading with New ISIN

The new ISIN will be effective for trades conducted on and from the Ex-Date, i.e., March 21, 2025. All transactions from this date onwards will take place under the new ISIN number allotted to the sub-divided equity shares of Re. 1/- each.

Background and Corporate Action

The sub-division of equity shares was initiated as part of Shukra Pharmaceuticals’ strategic move to enhance liquidity and affordability for its investors. By reducing the face value from Rs. 10/- to Re. 1/-, the company aims to encourage broader participation from retail investors and improve the marketability of its shares.

Notice from BSE Limited

The details regarding the new ISIN were communicated by BSE Limited via Notice No. 20250319-43 dated March 19, 2025. This notice follows a previous intimation from the exchange via Notice No. 20250312-49 dated March 12, 2025, which highlighted the impending approval of the sub-division of equity shares.

Importance of New ISIN for Investors

The assignment of a new ISIN ensures smooth trading and seamless transition for existing shareholders. Investors holding Shukra Pharmaceuticals' equity shares need to note that trades conducted after March 21, 2025, will be aligned with the new ISIN, and shares with the old ISIN will no longer be tradable post this date.

Corporate Governance and Compliance

Shukra Pharmaceuticals has demonstrated its commitment to regulatory compliance by ensuring that all necessary approvals and disclosures were made in accordance with the guidelines set forth by SEBI (Securities and Exchange Board of India) and the Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Impact of Sub-Division on Shareholders

• Increased Liquidity: Lower face value increases the affordability of shares, making it more accessible for retail investors.
• Wider Participation: Broader investor participation can lead to higher trading volumes and improved liquidity.
• Enhanced Market Perception: Share sub-division often enhances market perception and adds flexibility for price movements.

Next Steps for Investors

1. Take Note of the New ISIN: Investors should update their trading platforms and ensure that they are trading under the new ISIN (INE551C01044) post March 21, 2025.
2. Review Portfolio Holdings: Ensure that holdings reflect the adjusted face value and correct ISIN details.
3. Monitor Corporate Announcements: Stay updated with further notifications from BSE and Shukra Pharmaceuticals.

About Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited is a leading pharmaceutical company engaged in the manufacturing and distribution of high-quality pharmaceutical formulations. The company has a state-of-the-art facility located in Rakanpur, Gujarat, and serves a wide range of domestic and international markets.

Conclusion

The sub-division of equity shares and the subsequent assignment of a new ISIN number (INE551C01044) by BSE Limited marks a significant corporate action for Shukra Pharmaceuticals Limited. With this change, effective from March 21, 2025, the company aims to enhance market liquidity and improve shareholder value. Investors are advised to stay informed and take note of the updated trading parameters to ensure smooth and seamless transactions.

The Upcoming IPOs in this week and coming weeks are Arisinfra Solutions Limited,Rapid Fleet Management Services, Active Infrastructures Limited, Desco Infratech Limited, ATC Energies System Limited, Shri Ahimsa Naturals Limited.

The Current active IPO are Grand Continental Hotels.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.